Loading... (0%)
About liver disease

Press releases

GENFIT: Major Milestone for the RESOLVE-IT Phase 3 Trial on the Recruitment of the Interim Analysis Cohort
Published on: 04/11/2018
GENFIT: Presentations at EASL 2018 Annual Congress Highlight Progress in NASH Diagnostics, Combination Therapies and Deep-learning Applications in Medical Imaging
Published on: 03/28/2018
2017: A year of very significant reinforcement of the cash position (€274M at 12.31.2017), with all programs in the Company’s pipeline moving forward
Published on: 03/13/2018
GENFIT: Official Launch of the NASH Pediatric Program, following PIP and PSP Agreement by EMA and FDA
Published on: 01/23/2018
GENFIT: Half-Year Report of Liquidity Contract with CIC
Published on: 01/12/2018
GENFIT: Announces its Financial Calendar for 2018
Published on: 01/12/2018
GENFIT: Additional Resources Allocated to the Liquidity Agreement
Published on: 12/08/2017
GENFIT: Contributing Significantly to the European LITMUS Initiative on NASH Biomarkers
Published on: 11/27/2017
GENFIT: Positive Outcome from the 18-month Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor
Published on: 11/22/2017
GENFIT completes a €180 million offering of bonds convertible into new shares and/or exchangeable for existing shares (“OCEANEs”) due 2022
Published on: 10/17/2017
  • Shareholders Letter
    N°8, October 2017
Corporate information
  • Analyst/Investor presentation
    October 2017
Financial information

If you want to contact our Press Relations team, please do not hesitate to send us a message.

Contact us